MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cncr.70360

Медицинская библиотека · Cancer · 2026

Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment-naive peripheral T-cell lymphoma: A multicenter, open-label, single-arm, phase 1b trial.

Gao Yan, Jiang Ming, Zhang Xuanye, Liu Lihong, Zhang Liling, Li Yufu, Wang Xin, Yan Xiaojing, Zhou Hui, Huang Huiqiang

СтатьяМногоцентровое исследованиеКлиническое исследование I фазыПеревод в очереди

Аннотация

BACKGROUND

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas. Most subtypes are generally associated with a poor prognosis when treated with standard chemotherapy.

METHODS

This study enrolled patients with untreated PTCL who received mitoxantrone hydrochloride liposome (Lipo-MIT) plus cyclophosphamide, vincristine, and prednisone (CMOP) every 4 weeks for six cycles. The study consisted of a 3 + 3 dose-escalation phase (Lipo-MIT at 12, 15, 18, and 21 mg/m2) and a specific dose-expansion phase (Lipo-MIT at the recommended phase 2 dose [RP2D]).

RESULTS

Between December 21, 2020, and November 17, 2022, 38 patients were enrolled. No dose-limiting toxicities were reported, and the RP2D was established at 18 mg/m2. Grade ≥3 treatment-related adverse events occurred in 33 (86.8%) patients, with the most common being neutrophil count decrease (76.3%) and white-cell count decrease (73.7%). No treatment-related deaths occurred. Among the 35 response-evaluable patients, the independent review committee-assessed complete response rate (CRR) was 54.3% (95% CI, 36.6%-71.2%), and the overall response rate (ORR) was 88.6% (95% CI, 73.3%-96.8%). For the 17 patients treated at RP2D, the CRR, ORR, median duration of CR, and median duration of response were 64.7% (95% CI, 38.3%-85.8%), 94.1% (95% CI, 71.3%-99.9%), 28.0 (95% CI, 9.8-46.3) months, and 28.0 (95% CI, 4.0-52.1) months, respectively. At a median follow-up of 23.8 months, the median progression-free survival was 20.8 (95% CI, 6.1-35.5) months, and the median overall survival was not reached. Lipo-MIT exhibited a favorable pharmacokinetics (PK) profile.

CONCLUSION

The CMOP regimen demonstrates a favorable PK profile, a manageable safety profile, and encouraging preliminary antitumor activity.

Для цитирования: Gao Yan, Jiang Ming, Zhang Xuanye, Liu Lihong, Zhang Liling, Li Yufu, Wang Xin, Yan Xiaojing, Zhou Hui, Huang Huiqiang. Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment-naive peripheral T-cell lymphoma: A multicenter, open-label, single-arm, phase 1b trial.. Cancer. 2026. DOI: 10.1002/cncr.70360.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.